These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 14587098

  • 21. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, Chai CY, Huang CH, Chen IJ.
    Prostate; 2009 May 01; 69(6):610-23. PubMed ID: 19143029
    [Abstract] [Full Text] [Related]

  • 22. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS.
    Prostate; 2003 Jun 01; 55(4):299-307. PubMed ID: 12712409
    [Abstract] [Full Text] [Related]

  • 23. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):935-40. PubMed ID: 18760546
    [Abstract] [Full Text] [Related]

  • 24. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice.
    Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ.
    Clin Cancer Res; 1996 Sep 01; 2(9):1627-36. PubMed ID: 9816342
    [Abstract] [Full Text] [Related]

  • 25. Differential metastasis-associated gene analysis of prostate carcinoma cells derived from primary tumor and spontaneous lymphatic metastasis in nude mice with orthotopic implantation of PC-3M cells.
    Chu JH, Sun ZY, Meng XL, Wu JH, He GL, Liu GM, Jiang XR.
    Cancer Lett; 2006 Feb 20; 233(1):79-88. PubMed ID: 15885894
    [Abstract] [Full Text] [Related]

  • 26. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H, Nguyen TH, Panasci L, Do P.
    Cancer; 2004 Dec 15; 101(12):2881-91. PubMed ID: 15529313
    [Abstract] [Full Text] [Related]

  • 27. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL, Gardner TA, Miao L, Balian G, Chung LW.
    Cancer Gene Ther; 2004 Feb 15; 11(2):148-55. PubMed ID: 14695756
    [Abstract] [Full Text] [Related]

  • 28. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
    Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S.
    Cancer Gene Ther; 2001 Sep 15; 8(9):628-35. PubMed ID: 11593331
    [Abstract] [Full Text] [Related]

  • 29. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
    Trofimova I, Dimtchev A, Jung M, Rosenthal D, Smulson M, Dritschilo A, Soldatenkov V.
    Cancer Res; 2002 Dec 01; 62(23):6879-83. PubMed ID: 12460902
    [Abstract] [Full Text] [Related]

  • 30. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW.
    J Urol; 1998 Jul 01; 160(1):220-9. PubMed ID: 9628654
    [Abstract] [Full Text] [Related]

  • 31. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
    Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH.
    Int J Oncol; 2004 Jan 01; 24(1):25-31. PubMed ID: 14654937
    [Abstract] [Full Text] [Related]

  • 32. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
    Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA.
    Endocr Relat Cancer; 2005 Sep 01; 12(3):631-43. PubMed ID: 16172196
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
    Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT.
    Prostate; 2003 Jun 15; 56(1):45-53. PubMed ID: 12746846
    [Abstract] [Full Text] [Related]

  • 38. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA.
    Cancer Lett; 2006 Dec 08; 244(2):274-88. PubMed ID: 16500022
    [Abstract] [Full Text] [Related]

  • 39. Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis.
    Narita S, Tsuchiya N, Saito M, Inoue T, Kumazawa T, Yuasa T, Nakamura A, Habuchi T.
    Prostate; 2008 Feb 15; 68(3):321-35. PubMed ID: 18175332
    [Abstract] [Full Text] [Related]

  • 40. Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice.
    Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ.
    Anticancer Res; 1999 Feb 15; 19(2A):893-902. PubMed ID: 10368631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.